Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Sancuso — Revenue

Other product segments

Kristalose
$3.12M-28.7%
Vibativ
$2.12M-29.4%
Talicia
$1.92M—
Caldolor
$896.71K-34.7%
Other revenue
$168.85K-94.6%
Acetadote
$66.67K+65.8%

Similar metrics at other companies

Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Embecta Corp. logo
EMBCSafety — Revenue
$34.3M+0.3%
Aurinia Pharmaceuticals logo
AUPHService Revenue — Revenue
$4.1M+64.0%
Aquestive Therapeutics, Inc. logo
AQSTUnited States — Revenue
$13.25M+155%
Embecta Corp. logo
EMBCSyringes — Revenue
$26.3M-8.7%
Aurinia Pharmaceuticals logo
AUPHU.S. — Revenue
$65.96M+25.6%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's sancuso — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's sancuso — revenue?
Cumberland Pharmaceuticals (CPIX) reported sancuso — revenue of $2.93M in Q1 2026.
How has Cumberland Pharmaceuticals's sancuso — revenue changed year-over-year?
Cumberland Pharmaceuticals's sancuso — revenue increased by 29.8% year-over-year, from $2.26M to $2.93M.
What does sancuso — revenue mean?
This metric represents the total gross sales generated from the commercialization of a specific branded pharmaceutical product within the company's specialty portfolio. It serves as a key indicator of market adoption, product lifecycle performance, and the effectiveness of the dedicated sales force in the hospital and acute care channels. Monitoring this revenue stream helps investors assess the product's contribution to overall top-line growth and its competitive positioning in the therapeutic market.